Clinical Trial Update: Safety and Efficacy Study of Single-Dose Oral CEM-101 in Patients With Uncomplicated Urogenital Gonorrhea [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and efficacy of a single-dose oral CEM-101 in patients with uncomplicated urogenital gonorrhea has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gonorrhea

Drugs mentioned

• CEM-101

Snippet

Sponsor: Melinta Therapeutics, Inc. | Conditions: Uncomplicated Urogenital Gonorrhea | Phase 2 | Status: COMPLETED